Olema Oncology
Wenxiang Zeng has over 20 years of experience in analytical chemistry in the pharmaceutical industry. Wenxiang has held positions at companies such as Olema Oncology, Alexza Pharmaceuticals, Gilead Sciences, Neosil Company, and American Peptide. Their roles have included Senior Director, Director, Senior Research Scientist, and Senior Analytical Chemist, where they led analytical method development, validation, and transfer for clinical projects, and supported drug substance and product development.
Wenxiang Zeng is currently pursuing a Doctor of Philosophy (Ph.D.) degree in Analytical Chemistry at The University of New Mexico.
This person is not in any teams
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.